These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23554447)

  • 1. Cisplatin resistance associated with PARP hyperactivation.
    Michels J; Vitale I; Galluzzi L; Adam J; Olaussen KA; Kepp O; Senovilla L; Talhaoui I; Guegan J; Enot DP; Talbot M; Robin A; Girard P; Oréar C; Lissa D; Sukkurwala AQ; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Dessen P; Saparbaev M; Soria JC; Castedo M; Kroemer G
    Cancer Res; 2013 Apr; 73(7):2271-80. PubMed ID: 23554447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
    Michels J; Vitale I; Senovilla L; Enot DP; Garcia P; Lissa D; Olaussen KA; Brenner C; Soria JC; Castedo M; Kroemer G
    Cell Cycle; 2013 Mar; 12(6):877-83. PubMed ID: 23428903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCL-1 dependency of cisplatin-resistant cancer cells.
    Michels J; Obrist F; Vitale I; Lissa D; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Castedo M; Kroemer G
    Biochem Pharmacol; 2014 Nov; 92(1):55-61. PubMed ID: 25107702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of arginine-specific ADP-ribosyltransferase 1 and poly(ADP-ribose) polymerase-1 on apoptosis induced by cisplatin in CT26 cells.
    Kuang J; Wang YL; Xiao M; Tang Y; Chen WW; Song GL; Yang X; Li M
    Oncol Rep; 2014 May; 31(5):2335-43. PubMed ID: 24676941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
    Majuelos-Melguizo J; Rodríguez MI; López-Jiménez L; Rodríguez-Vargas JM; Martí Martín-Consuegra JM; Serrano-Sáenz S; Gavard J; de Almodóvar JM; Oliver FJ
    Oncotarget; 2015 Mar; 6(7):4790-803. PubMed ID: 25576921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
    Kim J; Long KE; Tang K; Padanilam BJ
    Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
    Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
    J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
    Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
    PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
    Shan L; Li X; Liu L; Ding X; Wang Q; Zheng Y; Duan Y; Xuan C; Wang Y; Yang F; Shang Y; Shi L
    Oncogene; 2014 Jun; 33(24):3205-16. PubMed ID: 23851505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
    Matsunaga T; Yamaji Y; Tomokuni T; Morita H; Morikawa Y; Suzuki A; Yonezawa A; Endo S; Ikari A; Iguchi K; El-Kabbani O; Tajima K; Hara A
    Free Radic Res; 2014 Nov; 48(11):1371-85. PubMed ID: 25156503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
    Chen S; Liu X; Gong W; Yang H; Luo D; Zuo X; Li W; Wu P; Liu L; Xu Q; Ji A
    Oncol Rep; 2013 Jan; 29(1):260-8. PubMed ID: 23117577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines.
    Gambi N; Tramontano F; Quesada P
    Biochem Pharmacol; 2008 Jun; 75(12):2356-63. PubMed ID: 18468580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
    Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
    Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrogen peroxide-induced poly(ADP-ribosyl)ation regulates osteogenic differentiation-associated cell death.
    Robaszkiewicz A; Erdélyi K; Kovács K; Kovács I; Bai P; Rajnavölgyi E; Virág L
    Free Radic Biol Med; 2012 Oct; 53(8):1552-64. PubMed ID: 22940495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of p38 signaling and poly(ADP-ribosyl)ation-induced metabolic collapse in the osteogenic differentiation-coupled cell death pathway.
    Robaszkiewicz A; Valkó Z; Kovács K; Hegedűs C; Bakondi E; Bai P; Virág L
    Free Radic Biol Med; 2014 Nov; 76():69-79. PubMed ID: 25078118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.